Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Thorsten, Ruppert"'
Autor:
Doris Katharina Henn, Thorsten Ruppert
Publikováno v:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 66:28-37
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8bb4f19a5da1bd2057c2769af3019c3
https://doi.org/10.1007/s00103-022-03625-9
https://doi.org/10.1007/s00103-022-03625-9
Autor:
Georg Gdynia, Sven W. Sauer, Jürgen Kopitz, Dominik Fuchs, Katarina Duglova, Thorsten Ruppert, Matthias Miller, Jens Pahl, Adelheid Cerwenka, Markus Enders, Heimo Mairbäurl, Marcin M. Kamiński, Roland Penzel, Christine Zhang, Jonathan C. Fuller, Rebecca C. Wade, Axel Benner, Jenny Chang-Claude, Hermann Brenner, Michael Hoffmeister, Hanswalter Zentgraf, Peter Schirmacher, Wilfried Roth
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
HMBG1 is a protein expressed in natural killer cells and is important in immunosurveillance. In this study, the authors show that HMGB1 binds to and inhibits PKM2, resulting in a block in aerobic glycolysis and ultimately cell death.
Externí odkaz:
https://doaj.org/article/6d0982f20a704f85b9b090631aa6eb7d
Autor:
Nathalie Lambot, Jacquelyn Awigena-Cook, Tatiana Reimer, Annelie Persson, Julien Romanetto, Beatrix Friedeberg, Virginia Acha, Shera Dandapat, Thorsten Ruppert, Caroline Correas, Keith Wonnacott, Tobias Fleischmann, Christa Holzhauser, Ariane Galaup, Fátima Montes, Silvia Garcia, Pär Tellner, Stuart G Beattie
Publikováno v:
Cell and Gene Therapy Insights. 7:1093-1106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69c84caa440d8e85b8d8907699d337fd
https://doi.org/10.18609/cgti.2021.143
https://doi.org/10.18609/cgti.2021.143
Publikováno v:
Bundesgesundheitsblatt, Gesundheitsforschung, GesundheitsschutzLiteratur.
In the European Union (EU), 27 May 2014 was a significant date for clinical trials. Since that day, the EU Clinical Trials Regulation 536/2014 (EU-CTR) officially came into force. The new EU-CTR replaces EU Directive 2001/20/EC and fundamentally refo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c78447f00cb1575204cafe20f847dac
https://pubmed.ncbi.nlm.nih.gov/36449064
https://pubmed.ncbi.nlm.nih.gov/36449064
Autor:
Marcin M. Kamiński, Sven W. Sauer, Marian Kamiński, Silvana Opp, Thorsten Ruppert, Paulius Grigaravičius, Przemysław Grudnik, Hermann-Josef Gröne, Peter H. Krammer, Karsten Gülow
Publikováno v:
Cell Reports, Vol 2, Iss 5, Pp 1300-1315 (2012)
Mitochondria-originating reactive oxygen species (ROS) control T cell receptor (TCR)-induced gene expression. Here, we show that TCR-triggered activation of ADP-dependent glucokinase (ADPGK), an alternative, glycolytic enzyme typical for Archaea, med
Externí odkaz:
https://doaj.org/article/96ce577eec5b4fd6998e231b2ec9cac5
Autor:
Ali Tunç Tuncel, Thorsten Ruppert, Bei-Tzu Wang, Jürgen Günther Okun, Stefan Kölker, Marina Alexandra Morath, Sven Wolfgang Sauer
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0128770 (2015)
Maleic acid (MA) has been shown to induce Fanconi syndrome via disturbance of renal energy homeostasis, though the underlying pathomechanism is still under debate. Our study aimed to examine the pathomechanism underlying maleic acid-induced nephrotox
Externí odkaz:
https://doaj.org/article/de5a5c61ffe84299be878ad31253e2bb
Publikováno v:
GMS German Medical Science, Vol 10, p Doc04 (2012)
In 2007 the Association of Research-Based Pharmaceutical Companies (vfa) published recommendations to improve the quality and transparency of non-interventional studies. These recommendations include quality assurance measures, in particular with res
Externí odkaz:
https://doaj.org/article/80fa0fb03f844fff8ea757933230f3fa
Publikováno v:
Therapeutic Innovation & Regulatory Science. 50:769-776
Focused interviews were conducted with global pharmaceutical company representatives in order to derive a consistent view on drug target identification/validation challenges, collaborative strategies, and future developments in a precompetitive space
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d88aa636a1cd96b24f1c2f39518142
https://doi.org/10.1177/2168479016651298
https://doi.org/10.1177/2168479016651298
Publikováno v:
Advances in Precision Medicine. 1
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases. Medicine and drug development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46381978d703f84a59801aed53b951fe
https://doi.org/10.18063/apm.2016.02.004
https://doi.org/10.18063/apm.2016.02.004
Autor:
Peter Schirmacher, Thorsten Ruppert, Jens Pahl, Axel Benner, Jonathan C. Fuller, Katarina Duglova, Jenny Chang-Claude, Roland Penzel, Adelheid Cerwenka, Hanswalter Zentgraf, Hermann Brenner, Heimo Mairbäurl, Michael Hoffmeister, Georg Gdynia, Marcin Kamiński, Wilfried Roth, Dominik Fuchs, Markus Enders, Rebecca C. Wade, Sven W. Sauer, Jürgen Kopitz, Matthias Miller, Christine Zhang
Publikováno v:
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
The high-mobility group box 1 (HMGB1) protein has a central role in immunological antitumour defense. Here we show that natural killer cell-derived HMGB1 directly eliminates cancer cells by triggering metabolic cell death. HMGB1 allosterically inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41d88653f9c7fa0d258f51328e81fb2
http://europepmc.org/articles/PMC4786644
http://europepmc.org/articles/PMC4786644